Octavio Espinoza - Dec 13, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Financial Officer
Signature
/s/ Andrew Reardon, Attorney-in-Fact for Octavio Espinoza
Stock symbol
LGND
Transactions as of
Dec 13, 2022
Transactions value $
$0
Form type
4
Date filed
12/15/2022, 05:13 PM
Previous filing
Dec 1, 2022
Next filing
Dec 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +11K +143.42% $0.00 18.7K Dec 13, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Award $0 +20K $0.00 20K Dec 13, 2022 Common Stock 20K $63.62 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three equal annual installments on December 5, 2023; December 5, 2024; and December 5, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F2 Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter.